David Hallal - Alexion Pharmaceuticals CEO and Director
CEO
Mr. David L. Hallal is Chief Executive Officer Director of Alexion Pharmaceuticals Inc. since April 1 2015. He was with Alexion since June 2006 and has served as Chief Executive Officer since April 2015. Mr. Hallal has also been a member of the Board of Directors since September 2014. Since joining Alexion Mr. Hallal served as Chief Operating Office from September 2014 to April 2015 and in senior commercial positions including Senior Vice President US Commercial Operations from June 2006 until November 2008 Senior Vice President Commercial Operations Americas from November 2008 to May 2010 Senior Vice President Global Commercial Operations from May 2010 until October 2012 and then Executive Vice President and Chief Commercial Officer from October 2012 to September 2014. Prior to joining Alexion Mr. Hallal served as Vice President Sales at OSI Eyetech from April 2004 until June 2006 where he led the U.S. launch of a firstinclass antiVEGF therapy for agerelated macular degeneration. Prior to OSI Eyetech from 1992 until 2004 Mr. Hallal held various sales and marketing leadership positions at Amgen and Biogen Idec where he was involved in multiple product launches in the areas of hematology oncology nephrology and immunology since 2015.
| Age | 48 |
| Tenure | 9 years |
| Phone | 475 230-2596 |
| Web | www.alexion.com |
Alexion Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 10.08 % which means that it generated a profit of $10.08 on every $100 spent on assets. This is normal as compared to the sector avarege. Similarly, it shows a return on stockholder's equity (ROE) of 4.43 %, meaning that it created $4.43 on every $100 dollars invested by stockholders. Alexion Pharmaceuticals' management efficiency ratios could be used to measure how well Alexion Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 2.88 B in liabilities with Debt to Equity (D/E) ratio of 0.23, which may suggest the company is not taking enough advantage from borrowing. Alexion Pharmaceuticals has a current ratio of 4.43, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Alexion Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Alexion Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Alexion Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Alexion to invest in growth at high rates of return. When we think about Alexion Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 2 records | CEO Age | ||
| Carlos Brito | Anheuser Busch Inbev | 60 | |
| Brendan Whitworth | Anheuser Busch Inbev | 45 | |
Management Performance
| Return On Equity | 4.43 | |||
| Return On Asset | 10.08 |
Alexion Pharmaceuticals Leadership Team
Elected by the shareholders, the Alexion Pharmaceuticals' board of directors comprises two types of representatives: Alexion Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alexion. The board's role is to monitor Alexion Pharmaceuticals' management team and ensure that shareholders' interests are well served. Alexion Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alexion Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Edward Miller, Senior Vice President Global Chief Compliance Officer | ||
| David Anderson, CFO | ||
| Felix Baker, Director | ||
| Dominique Monnet, Senior Vice President Chief Marketing Officer | ||
| Saqib Islam, Senior Vice President Chief Strategy and Portfolio Officer | ||
| John Orloff, Executive Vice President Head of Research and Development | ||
| Ludwig Hantson, CEO, Director | ||
| Vikas Sinha, CFO, Executive Vice President | ||
| Andreas Rummelt, Independent Director | ||
| Julie ONeill, Executive Vice President - Global Operations | ||
| Brian Goff, Chief Commercial Officer | ||
| Clare Carmichael, Chief Human Resource Officer, Senior Vice President | ||
| Deborah Dunsire, Independent Director | ||
| Ellen Chiniara, Executive Vice President General Counsel, Corporate Secretary | ||
| Leonard Bell, CEO, Treasurer, Director | ||
| Paul Friedman, Director | ||
| Christopher Coughlin, Independent Director | ||
| Martin Mackay, Global Head of RandD and Executive VP | ||
| Heidi Wagner, Senior Vice President - Global Governmental Affairs | ||
| Ann Veneman, Independent Director | ||
| Paul Clancy, CFO | ||
| AnneMarie Law, Chief Patient and Employee Experience Officer, Executive Vice President | ||
| Francois Nader, Director | ||
| Judith Reinsdorf, Director | ||
| Indrani Franchini, Executive Vice President Chief Compliance Officer | ||
| John Moriarty, Senior Vice President General Counsel | ||
| Alvin Parven, Independent Director | ||
| Michele Burns, Independent Director | ||
| David Hallal, CEO and Director | ||
| Douglas Norby, Lead Independent Director | ||
| David Brennan, Independent Director | ||
| Carsten Thiel, Senior Vice President EMEA and Asia Pacific | ||
| John Mollen, Director |
Alexion Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Alexion Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 4.43 | |||
| Return On Asset | 10.08 | |||
| Profit Margin | 10.89 % | |||
| Operating Margin | 52.12 % | |||
| Current Valuation | 39.17 B | |||
| Shares Outstanding | 221.02 M | |||
| Shares Owned By Insiders | 0.34 % | |||
| Shares Owned By Institutions | 88.27 % | |||
| Number Of Shares Shorted | 8.46 M | |||
| Price To Earning | 58.24 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Alexion Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Alexion Pharmaceuticals' short interest history, or implied volatility extrapolated from Alexion Pharmaceuticals options trading.
Pair Trading with Alexion Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alexion Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alexion Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Autodesk could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Autodesk when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Autodesk - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Autodesk to buy it.
The correlation of Autodesk is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Autodesk moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Autodesk moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Autodesk can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Other Consideration for investing in Alexion Stock
If you are still planning to invest in Alexion Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Alexion Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |